FGFR1 amplification and the progression of non-invasive to invasive breast cancer

Breast Cancer Research

Volumn 14, Issue 6, 2012, Pages

  Gru, Alejandro A ^a   Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MYC PROTEIN;

BREAST CANCER; CANCER SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE BREAST CANCER; NONHUMAN; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; BREAST TUMOR; FEMALE; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84869102066     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3340     Document Type: Editorial

References (16)

1. Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 2012, 14:R115. 10.1186/bcr3239, 22863309.
2. Allred DC. Biological features of human premalignant breast disease and the progression to cancer. Diseases of the Breast 2009, 323-334. New York: Lippincott Williams and Wilkins, Harris JR, Lippman ME, Morrow M, Hellman S, Osborne CK, 4.
3. American Cancer Society Breast Cancer Facts and Figures 2011-2012. Atlanta, GA: American Cancer Society Inc, American Cancer Society.
4. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 2010, 102:161-169. 10.1093/jnci/djp485, 20071686.
5. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007, 117:3155-3163. 10.1172/JCI33295, 2045618, 17975657.
6. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012, 72:4574-4586. 10.1158/0008-5472.CAN-12-0636, 22751464.
7. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006, 6:245. 10.1186/1471-2407-6-245, 1626089, 17040570.
8. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002, 15:1318-1325. 10.1097/01.MP.0000038462.62634.B1, 12481013.
9. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 2002, 157:703-714. 10.1083/jcb.200107119, 2173854, 12011115.
10. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 2005, 171:663-673. 10.1083/jcb.200505098, 2171554, 16301332.
11. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007, 9:R23. 10.1186/bcr1665, 1868920, 17397528.
12. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094. 10.1158/0008-5472.CAN-09-3746, 2832818, 20179196.
13. Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009, 10:632-644. 10.2174/138945009788680419, 19601767.
14. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Letessier A, Ginestier C, Monville F, Esteyriès S, Adélaïde J, Esterni B, Henry C, Ethier SP, Bibeau F, Mozziconacci MJ, Charafe-Jauffret E, Jacquemier J, Bertucci F, Birnbaum D, Theillet C, Chaffanet M. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005, 3:655-667. 10.1158/1541-7786.MCR-05-0128, 16380503.
15. Gru AA, Salavaggione AL, Hoog J, Snyder J, Tao Y, Ellis M, Allred DC. Amplification of FGFR1 gene and its relationship with gene expression and clinical significance in breast cancer. Modern Pathol 2010, 23(1s):48A.
16. Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res 2012, 14:208. 10.1186/bcr3139, 22731805.